Answers are grounded in this paper and cite their sources.
Single-centre study reports real-world pharmacokinetics of efanesoctocog alfa in patients with haemophilia A, suggesting optimized management strategies.
INTRODUCTION: Efanesoctocog alfa (EFA) is an ultra-extended half-life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real-world data remain important to better characterize PK profiles across patient subgroups. AIM: To report real-world PK data for EFA. METHODS: In this single-centre study, adults and children (>6 years) with severe haemophilia A at Strasbourg University Hospital switched from a prior FVIII product to EFA. A simplified PK assessment was performed once or twice per patient after a 50 IU/kg infusion. FVIII activity was measured pre-infusion and at 3, 24, 96 h, and 7 days post-infusion. Patients were reassessed at steady state after ≥6 weeks. RESULTS: In adults, mean (range) half-life was 52 h (35-62). Mean incremental recovery at 3 h was 2.98 IU/dL per IU/kg (1.85-3.82). Mean FVIII trough levels were 17 IU/dL (5-27) at switch and 19 IU/dL (10-27) at steady state. Significant interindividual variability was observed. Half-life correlated positively with VWF:Ag levels (r = 0.63; p < 0.05) and body weight (r = 0.62; p < 0.05). In children, mean half-life was 53 h (48-59), mean recovery 2.05 IU/dL per IU/kg (1.86-2.26), and trough levels 13-14 IU/dL. CONCLUSIONS: PK profiles matched or exceeded those reported in the XTEND studies, with a slightly longer half-life and higher trough FVIII levels. Notable interindividual variability highlights the value of PK assessments, even for ultra-extended half-life FVIII, to optimize individualized patient management.
No takes yet. Share an insight, caveat, or question.
Sattler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: